NCT06717958 (PIVOT) is a Phase 2 clinical trial of Ivosidenib 250 MG (milligram) in AML, sponsored by Technische Universität Dresden.

Who is sponsoring NCT06717958?

NCT06717958 is sponsored by Technische Universität Dresden.

What drugs are being tested in NCT06717958?

Interventions in NCT06717958: Ivosidenib 250 MG (milligram).

Is NCT06717958 still recruiting?

NCT06717958 is currently recruiting now. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT06717958: PIVOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Recruiting now Phase 2 Last updated 2 July 2025

What this trial tests

Phase 2 trial testing Ivosidenib 250 MG (milligram) in AML in 76 participants. Currently enrolling.

Timeline

17 June 2025

Primary endpoint
1 October 2029

1 February 2030

Quick facts

Lead sponsor	Technische Universität Dresden
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	17 June 2025
Primary completion	1 October 2029
Estimated completion	1 February 2030
Sites	12 locations across Germany

Drugs / interventions tested

Ivosidenib 250 MG (milligram) — full drug profile →

Conditions studied

AML — all drugs for AML →
MDS — all drugs for MDS →

Sponsor

Technische Universität Dresden — full company profile →

Who can join

Adults 18 to 75, any sex, with AML or MDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.
Rankin AW, Keating AK, Abu-Arja RF, Thakar MS, et al · · 2026 · PMID 41716469 · DOI 10.1016/j.omton.2026.201141
Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy.
Tang J, Ye X, Xu Z, Min T, et al · · 2025 · PMID 41199817 · DOI 10.3389/fphar.2025.1672524

Verify or expand the search:

Other recruiting trials for AML

Currently open trials in the same condition.

NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
NCT06973668 — A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophospham · Phase 2 · recruiting
NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
NCT06972641 — Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 2, PHASE3 · recruiting

Other Technische Universität Dresden trials

Trials by the same sponsor.

NCT07150598 — Immune-Marker Platform for Patients With Advanced Lung Cancer · not yet recruiting
NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
NCT03865277 — Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging · Phase 2 · not yet recruiting
NCT06293170 — Automated Screening for Clinically Ascertained Loss of Cerebral Functions · NA · not yet recruiting
NCT06377462 — Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06717958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technische Universität Dresden
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06717958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing